Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

PARP inhibition enhances tumor cell–intrinsic immunity in ERCC1-deficient non–small cell lung cancer
Roman M. Chabanon, Gareth Muirhead, Dragomir B. Krastev, et al.
Journal of Clinical Investigation (2018) Vol. 129, Iss. 3, pp. 1211-1228
Open Access | Times Cited: 266

Showing 1-25 of 266 citing articles:

Molecular mechanisms and cellular functions of cGAS–STING signalling
Karl‐Peter Hopfner, Veit Hornung
Nature Reviews Molecular Cell Biology (2020) Vol. 21, Iss. 9, pp. 501-521
Closed Access | Times Cited: 1296
DNA sensing by the cGAS–STING pathway in health and disease
Mona Motwani, Scott Pesiridis, Katherine A. Fitzgerald
Nature Reviews Genetics (2019) Vol. 20, Iss. 11, pp. 657-674
Closed Access | Times Cited: 1086
Consensus guidelines for the definition, detection and interpretation of immunogenic cell death
Lorenzo Galluzzi, Ilio Vitale, Sarah H. Warren, et al.
Journal for ImmunoTherapy of Cancer (2020) Vol. 8, Iss. 1, pp. e000337-e000337
Open Access | Times Cited: 834
Detection of immunogenic cell death and its relevance for cancer therapy
Jitka Fučíková, Oliver Kepp, Lenka Kašíková, et al.
Cell Death and Disease (2020) Vol. 11, Iss. 11
Open Access | Times Cited: 717
Inflammatory microenvironment remodelling by tumour cells after radiotherapy
Martin McLaughlin, Emmanuel C. Patin, Malin Pedersen, et al.
Nature reviews. Cancer (2020) Vol. 20, Iss. 4, pp. 203-217
Closed Access | Times Cited: 603
A decade of clinical development of PARP inhibitors in perspective
Joaquı́n Mateo, Christopher J. Lord, Violeta Serra, et al.
Annals of Oncology (2019) Vol. 30, Iss. 9, pp. 1437-1447
Open Access | Times Cited: 559
PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer
Constantia Pantelidou, Olmo Sonzogni, Mateus de Oliveira Taveira, et al.
Cancer Discovery (2019) Vol. 9, Iss. 6, pp. 722-737
Open Access | Times Cited: 530
PARP and PARG inhibitors in cancer treatment
Dea Slade
Genes & Development (2020) Vol. 34, Iss. 5-6, pp. 360-394
Open Access | Times Cited: 516
PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance
Maddison Rose, Joshua T. Burgess, Kenneth J. O’Byrne, et al.
Frontiers in Cell and Developmental Biology (2020) Vol. 8
Open Access | Times Cited: 503
STING: a master regulator in the cancer-immunity cycle
Yuanyuan Zhu, Xiang An, Xiao Zhang, et al.
Molecular Cancer (2019) Vol. 18, Iss. 1
Open Access | Times Cited: 296
Immunological impact of cell death signaling driven by radiation on the tumor microenvironment
María E. Rodríguez-Ruiz, Ilio Vitale, Kevin J. Harrington, et al.
Nature Immunology (2019) Vol. 21, Iss. 2, pp. 120-134
Closed Access | Times Cited: 296
The cGAS–STING pathway and cancer
Natasha Samson, Andrea Ablasser
Nature Cancer (2022) Vol. 3, Iss. 12, pp. 1452-1463
Closed Access | Times Cited: 278
The plasticity of DNA replication forks in response to clinically relevant genotoxic stress
Matteo Berti, David Cortez, Massimo Lopes
Nature Reviews Molecular Cell Biology (2020) Vol. 21, Iss. 10, pp. 633-651
Closed Access | Times Cited: 273
STING pathway agonism as a cancer therapeutic
Blake Flood, Emily F. Higgs, Shuyin Li, et al.
Immunological Reviews (2019) Vol. 290, Iss. 1, pp. 24-38
Open Access | Times Cited: 265
Structural basis for allosteric PARP-1 retention on DNA breaks
Levani Zandarashvili, Marie-France Langelier, Uday Kiran Velagapudi, et al.
Science (2020) Vol. 368, Iss. 6486
Open Access | Times Cited: 265
Hypoxia-inducible factors: master regulators of hypoxic tumor immune escape
Qinghua Wu, You Li, Eugenie Nepovimová, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 251
Dendritic cell subsets in cancer immunity and tumor antigen sensing
Annalisa Del Prete, Valentina Salvi, Alessandra Soriani, et al.
Cellular and Molecular Immunology (2023) Vol. 20, Iss. 5, pp. 432-447
Open Access | Times Cited: 246
DNA Damage and Cancer Immunotherapy: A STING in the Tale
Timo Reisländer, Florian J. Groelly, Madalena Tarsounas
Molecular Cell (2020) Vol. 80, Iss. 1, pp. 21-28
Open Access | Times Cited: 240
Development of Immunotherapy Combination Strategies in Cancer
Timothy A. Yap, Eileen E. Parkes, Weiyi Peng, et al.
Cancer Discovery (2021) Vol. 11, Iss. 6, pp. 1368-1397
Open Access | Times Cited: 232
Trial watch: TLR3 agonists in cancer therapy
Julie Le Naour, Lorenzo Galluzzi, Laurence Zitvogel, et al.
OncoImmunology (2020) Vol. 9, Iss. 1
Open Access | Times Cited: 224
Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer
Neha Chopra, Holly Tovey, Alex Pearson, et al.
Nature Communications (2020) Vol. 11, Iss. 1
Open Access | Times Cited: 223
Trial watch: STING agonists in cancer therapy
Julie Le Naour, Laurence Zitvogel, Lorenzo Galluzzi, et al.
OncoImmunology (2020) Vol. 9, Iss. 1
Open Access | Times Cited: 221
Targeting the DNA damage response in immuno-oncology: developments and opportunities
Roman M. Chabanon, Mathieu Rouanne, Christopher J. Lord, et al.
Nature reviews. Cancer (2021) Vol. 21, Iss. 11, pp. 701-717
Closed Access | Times Cited: 211
Research Advances in How the cGAS-STING Pathway Controls the Cellular Inflammatory Response
Dongshan Wan, Wei Jiang, Junwei Hao
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 206
Comprehensive elaboration of the cGAS-STING signaling axis in cancer development and immunotherapy
Juyan Zheng, Junluan Mo, Tao Zhu, et al.
Molecular Cancer (2020) Vol. 19, Iss. 1
Open Access | Times Cited: 206
Page 1 - Next Page

Scroll to top